Fluorinated ligands for targeting peripheral benzodiazepine receptors

(19)

(11)

EP 2 752 415 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	15.11.2017 Bulletin 2017/46

(45)	Mention of the grant of the patent:
	11.10.2017 Bulletin 2017/41

(21)	Application number: 14155943.5

(22)	Date of filing: 24.08.2007

(51)

International Patent Classification (IPC):

C07D 471/04^(2006.01)
C07B 59/00^(2006.01)
A61K 31/498^(2006.01)
A61K 31/5025^(2006.01)
A61K 31/53^(2006.01)
A61P 25/28^(2006.01)

C07D 487/04^(2006.01)
A61K 31/437^(2006.01)
A61K 31/4985^(2006.01)
A61K 31/519^(2006.01)
A61P 25/00^(2006.01)
A61P 35/00^(2006.01)

(54)	Fluorinated ligands for targeting peripheral benzodiazepine receptors Fluorierte Liganden für periphere Benzodiazepin-Rezeptoren Ligands fluorés pour des récepteurs péripheriques des benzodiazépines

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30)

Priority:

24.08.2006 AU 2006904617 P
22.12.2006 AU 2006907288 P

(43)	Date of publication of application:
	09.07.2014 Bulletin 2014/28

(60)	Divisional application:
	17195772.3

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	07784851.3 / 2054060

(73)	Proprietor: AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION
	Lucas Heights New South Wales 2234 (AU)

(72)	Inventors:
	Katsifis, Andrew Lugarno, New South Wales 2210 (AU) Fookes, Christopher John Reginald Grays Point, New South Wales 2232 (AU) Pham, Tien Quoc Menai, New South Wales 2234 (AU) Greguric, Ivan Damir Oatley, New South Wales 2223 (AU) Mattner, Maria Filomena Pereira Soares Barden Ridge, New South Wales 2234 (AU)

(74)	Representative: Elend, Almut Susanne et al
	Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ Cambridge, Cambridgeshire CB4 0WZ (GB)

(56)

References cited: :

EP-A1- 0 050 563
WO-A1-2007/134362

WO-A1-2006/051063
US-B1- 6 379 649

FOOKES ET AL.: "Synthesis and Biological Evaluation of Substituted [18 F]Imidazo[1,2-a]pyridines and [18 F]Pyrazolo[1,5-a]pyrimidines for the Study of the Peripheral Benzodiazepine Receptor Using Positron Emission Tomography", J. MED. CHEM., vol. 51, no. 13, 17 June 2008 (2008-06-17) , pages 3700-3712, XP055121033, ISSN: 0022-2623, DOI: 10.1021/jm7014556
SELLERI ET AL.: "2-Arylpyrazolo[1,5-a]pyrimidin-3-yl Acetamides. New Potent and Selective Peripheral Benzodiazepine Receptor Ligands", BIOORG. MED. CHEM., vol. 9, no. 10, 1 January 2001 (2001-01-01), pages 2661-2671, XP008090470, ISSN: 0968-0896, DOI: 10.1016/S0968-0896(01)00192-4
KOZIKOWSKI ET AL.: J. MED. CHEM., vol. 36, no. 20, 1 January 1993 (1993-01-01), pages 2908-2920, XP002118394, ISSN: 0022-2623, DOI: 10.1021/JM00072A010
PIKE ET AL.: "Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites-current status", NUCL. MED. BIOL., vol. 20, no. 4, 1 May 1993 (1993-05-01), pages 503-525, XP026310326, ISSN: 0969-8051, DOI: 10.1016/0969-8051(93)90082-6 [retrieved on 1993-05-01]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).